Explore how to tailor healthcare value stories to global market access strategies, addressing cultural nuances, reimbursement challenges, and varying regulatory frameworks. Emphasize the importance of localizing evidence and personalizing messages to align with each market’s access requirements and healthcare priorities. Key Topics:
Join us on December 5th at 11:00 AM ET for an exclusive webinar, “New Horizons of Model-Informed Drug Development in Rare Diseases,” hosted in partnership with Takeda and Kura Oncology. Model-informed drug development is revolutionizing the way we approach rare diseases, where traditional large-scale clinical trials may be impractical or even unethical. By integrating nonclinical … <a href="https://www.certara.com.cn/webinar/unlock-the-future-of-rare-diseases-drug-development/">Continued</a>
Physiologically Based Pharmacokinetic (PBPK) modelling is an integrative approach facilitating the optimal use of various in vitro and preclinical data to determine the first in human dose. Simcyp Discovery, a part of Simcyp family, is a user-friendly PBPK platform designed to integrate in vitro and preclinical data, enabling the prediction of drug pharmacokinetics (PK) in … <a href="https://www.certara.com.cn/webinar/physiologically-based-pharmacokinetic-modelling-an-integrative-approach-to-first-in-human-fih-studies-apac-webinar/">Continued</a>
Unlocking the Power of Storytelling in Healthcare Communication In the realm of healthcare communication, persuasion is key. Whether you are engaging with payers, providers, or policymakers, the ability to convey the value of a product effectively can make a pivotal difference. Storytelling plays a crucial role in achieving this, transforming complex data into a compelling … Continued
Physiologically-based pharmacokinetic modeling can be used to support bioequivalence (BE) assessment of complex and locally acting generic drugs.
On 2024 年 10 月 30 日, we hosted our Pinnacle 21 Enterprise (P21E) User Group Meeting (UGM) in Mainz, Germany, as part of the inaugural Certara Certainty Europe customer summit. We welcomed customers from pharmas, biotechs and CROs from across Europe and beyond – including representatives from data standards, statistical programming, and data management, as we aligned … Continued
Certara 提供先进的药物开发解决方案，帮助制药和生物技术公司加快从早期研究到成功获得市场批准的过程。Certara 的专家团队中不乏世界领先的科学家，其中有七位科学家在他们各自的领域中被公认为被引用次数最多的前 2% 的科学家*。我们带给客户的价值在于与业内规模最大的模型引导的药物开发团队合作，降低项目风险，缩短时间线，降低成本，并提高对新的疗法如何影响患者的科学理解。Certara 拥有灵活的操作模式，支持大型制药企业中的专业建模团队，并为新兴生物科技初创公司担任全面的药物开发管理者，为客户提供卓越的价值，助您快速前进。
Certara 软件产品包括行业黄金标准产品，已在全球超过 60,000 名最终用户中使用。我们的目标是利用先进的计算能力引领行业，改变药物开发模型，包括药物发现、生物模拟和临床数据自动化。
The Challenge Charles River, a global leader in drug development, sought to improve its pharmacokinetics (PK) analysis across its seven worldwide sites. With each site using its own systems, workflows, and procedures, the company recognized the opportunity to optimize consistency in PK analysis and reporting. By centralizing efforts and refining processes, Charles River aimed to … Continued
模型 系统药理学模型以基本质量-作用、机制 PK/PD 常微分方程系统的第一原理为基础。The model parameters and reactions include compartment volumes, ligand concentration and turnover rates, cell numbers and turnover rates, drug administration, target-mediated drug disposition on two cell types, and endogenous drug elimination (Figure 2). Continued
全球有超过 2,300 家生命科学公司，包括 23 家全球监管机构，选择 Certara 作为他们在 MIDD 解决方案方面的合作伙伴，这些解决方案包括生物模拟、数据科学软件和专业的药物开发服务。了解我们如何帮助公司重新定义现代医学的可能。
